|
06 Jul 2021 |
Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
|
|
06 Jul 2021 |
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
|
|
06 Jul 2021 |
Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
|
|
06 Jul 2021 |
First Patient Dosed with Gadeta's gamma delta TCR Cell Therapy
|
|
04 Jul 2021 |
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
|
|
04 Jul 2021 |
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
|
|
04 Jul 2021 |
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
|
|
04 Jul 2021 |
Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
|
|
03 Jul 2021 |
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
|
|
02 Jul 2021 |
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
|
|
02 Jul 2021 |
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
|
|
02 Jul 2021 |
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
|
|
02 Jul 2021 |
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
|
|
02 Jul 2021 |
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
|
|
02 Jul 2021 |
HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine
|
|
02 Jul 2021 |
LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
|
|
02 Jul 2021 |
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
|
|
02 Jul 2021 |
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
|
|
02 Jul 2021 |
Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
|
|
02 Jul 2021 |
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
|
